摘要
目的研究舒洛地特对治疗2型糖尿病肾病Ⅲ期尿微量白蛋白排泌率(UAER)的疗效。方法 93例糖尿病肾病Ⅲ期患者被随机分为三组,常规组29组,舒洛地特组33例,福辛普利组31例。疗程均为8周。结果治疗8周后,舒洛地特组UAER(63.54±23.39)μg/min较正常组(110.74±37.52)μg/min相比,有显著统计学意义(P<0.001);较福辛普利组(69.56±21.47)μg/min相比,无统计学意义(P>0.05)。结论舒洛地特可有效降低2型糖尿病肾病Ⅲ期患者的尿微量蛋白排泌率。
Objective To investigate the effect of sulodexide on the diabetic nephropathy patients with microalbuminuria. Methods 93 patients of type 2 diabetic nephropathy patients with microalbuminuria （20μg/min ≤ UAER〈200μg/min）were divided into three group according to the different treatment protocols： the regular group （29 patients）, the sulodexide group （33 patients） and the fosinopril group（31 patients）. The course of treatment were 8 weeks. Results The results in the sulodexide group （63.54±23.39）μg/min compared with its in the fosinopril group, had a significantly advantage on the UAER （P〈0.001）. But it was no significant difference between the sulodexide group and the fosinopril group （P〉0.05）. Conclusion The therapy of sulodexide could effectively decreased microalbuminuria in patient with type 2 diabetic nephropathy.
出处
《中国医药指南》
2013年第17期25-26,共2页
Guide of China Medicine
